HCC and angiogenesis: possible targets and future directions.
HCC and angiogenesis: possible targets and future directions.
复制标题
DOI：
10.1038/nrclinonc.2011.30
复制
发表时间：
2011-05
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
肝细胞癌是最常见的原发性肝脏肿瘤，众所周知，它对全身治疗耐药，即使在积极的局部治疗后也经常复发。HCCs的生长依赖于新血管的形成，而血管内皮生长因子在这一过程中起着关键作用。肿瘤中新血管形成的一个标志是其结构和功能的异常。这导致了以低氧分压为特征的异常肿瘤微环境。肝脏同时由动脉和静脉血液灌流，由此产生的异常微环境选择了更具侵袭性的恶性肿瘤。索拉非尼的抗血管内皮生长因子治疗是第一个系统治疗，证明提高了晚期肝癌患者的存活率。肝细胞癌治疗方面的这一重要进展为靶向药物的未来发展带来了希望和关键问题，包括其他抗血管生成药物，这些药物有望进一步提高这种侵袭性疾病的存活率。
Hepatocellular carcinoma (HCC), the most common primary liver tumor, is notoriously resistant to systemic therapies, and often recurs even after aggressive local therapies. HCCs rely on the formation of new blood vessels for growth, and VEGF is critical in this process. A hallmark of new vessel formation in tumors is their structural and functional abnormality. This leads to an abnormal tumor microenvironment characterized by low oxygen tension. The liver is perfused by both arterial and venous blood and the resulting abnormal microenvironment selects for more-aggressive malignancies. Anti-VEGF therapy with sorafenib was the first systemic therapy to demonstrate improved survival in patients with advanced-stage HCC. This important development in the treatment of HCC raises hope as well as critical questions on the future development of targeted agents including other antiangiogenic agents, which hold promise to further increase survival in this aggressive disease.
登录
查看更多内容
影响因子：
51.1
作者：
Faivre, Sandrine;Raymond, Eric;Cheng, Ann Lii
通讯作者：
Cheng, Ann Lii
索拉非尼对亚太地区晚期肝细胞癌患者的疗效和安全性：一项 III 期随机、双盲、安慰剂对照试验
影响因子：
51.1
作者：
Cheng, Ann-Lii;Kang, Yoon-Koo;Guan, Zhongzhen
通讯作者：
Guan, Zhongzhen
影响因子：
45.3
作者：
Abou-Alfa, Ghassan K.;Schwartz, Lawrence;Saltz, Leonard B.
通讯作者：
Saltz, Leonard B.
影响因子：
19.7
作者：
d'Assignies, Gaspard;Couvelard, Anne;Vilgrain, Valerie
通讯作者：
Vilgrain, Valerie
影响因子：
45.3
作者：
Allegra, Carmen J.;Yothers, Greg;Wolmark, Norman
通讯作者：
Wolmark, Norman